metricas

Radiología (English Edition)

Suggestions
Radiología (English Edition) Recommendations for the use of gadolinium-based contrast agents in magnetic reso...
Journal Information
Vol. 68. Issue 5.
(September - October 2026)
Cite
Cite
Share
Download PDF
More article options
Visits
1044
Vol. 68. Issue 5.
(September - October 2026)
Update in Radiology

Recommendations for the use of gadolinium-based contrast agents in magnetic resonance imaging of the central nervous system

Recomendaciones para el uso de medios de contraste basados en gadolinio en estudios con resonancia magnética del sistema nervioso central
Visits
1044
À. Roviraa,
Corresponding author
alex.rovira.idi@gencat.cat

Corresponding author.
, A. Ramosb, B. Asenjoc, A. Cabrerad, M. Drake-Péreze, R.F. Ocetef
a Sección de Neuroradiología, Servicio de Radiología, Hospital Universitario Vall d’Hebron, Barcelona, Spain
b Servicio de Neuroradiología, Hospital Universitario 12 de Octubre, Madrid, Spain
c Sección de Neurorradiología, Servicio de Radiología, Hospital Regional Universitario de Málaga, Málaga, Spain
d Sección Neurorradiología, HT Médica, Jaén, Spain
e Servicio de Radiodiagnóstico, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Sanitaria IDIVAL, Santander, Cantabria, Spain
f Sección de Neurorradiología Diagnóstica, Unidad de Gestión Clínica de Radiodiagnóstico, Hospital Universitario Virgen del Rocío, Sevilla, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

Gadolinium-based contrast agents (GBCAs) are essential for improving the diagnostic accuracy of magnetic resonance imaging (MRI) studies. Although traditionally regarded as highly safe, in recent years the marketing authorisation for certain linear GBCAs has been withdrawn, and the use of macrocyclic GBCAs has become subject to regulatory oversight. Current recommendations advocate the use of the lowest effective dose at all times. Central nervous system (CNS) pathology is the most common indication for MRI with GBCAs. However, clinical recommendations and best practices in this setting often lack a comprehensive approach. This document presents recommendations for the use of GBCAs in the main categories of CNS disease—namely neuro-oncological, inflammatory, infectious and vascular conditions—as well as in CNS angiographic studies. These recommendations have been developed by a nationally convened expert committee. It also highlights the importance of ensuring clinical and environmental safety in the use of these contrast media.

Keywords:
(MeSH)
Gadolinium
Magnetic resonance imaging
Magnetic resonance angiography
Central nervous system
Neoplasms
Multiple sclerosis
Vascular diseases
Environment
Water pollution
Resumen

Los medios de contraste basados en gadolinio (MCBG) son fundamentales para mejorar la precisión diagnóstica de los estudios de resonancia magnética (RM). Pese a que tradicionalmente se han considerado altamente seguros, en los últimos años se ha suspendido la comercialización de algunos MCBG lineales, y regulado el uso de los MCBG macrocíclicos, recomendándose utilizar siempre la dosis mínima efectiva. La patología del sistema nervioso central (SNC) constituye la indicación más habitual de la RM con MCBG; sin embargo, las recomendaciones y buenas prácticas clínicas en esta patología carecen de una visión integral. Este documento presenta recomendaciones para el uso de MCBG en las principales enfermedades del SNC (neurooncológicas, inflamatorias, infecciosas y vasculares) así como en estudios angiográficos del SNC, elaboradas por un Comité de Expertos de ámbito nacional. Asimismo, se destaca la importancia de garantizar la seguridad clínica y ambiental en el uso de estos medios de contraste.

Palabras clave:
(MeSH)
Gadolinio
Resonancia magnética
Angiografía por resonancia magnética
Sistema nervioso central
Tumores
Esclerosis múltiple
Enfermedades vasculares
Medio ambiente
Contaminación del agua

Article

These are the options to access the full texts of the publication Radiología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
N.M.S.A. Iyad, S.G. Alkhatib, M. Hjouj.
Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: literature review.
Eur J Radiol Open., 11 (2023),
[2]
L. Marti-Bonmati, E. Marti-Bonmati.
Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.
Radiologia., 59 (2017), pp. 469-477
[3]
R. Soler-Fernandez, C. Mendez-Diaz, E. Rodriguez-Garcia.
Extracellular gadolinium-based contrast agents.
Radiologia (Engl Ed)., 66 (2024), pp. S51-S64
[4]
J.E. Gutierrez, M. Rosenberg, J. Seemann, J. Breuer, D. Haverstock, J. Agris, et al.
Safety and efficacy of gadobutrol for contrast-enhanced magnetic resonance imaging of the central nervous system: results from a multicenter, double-blind, randomized, comparator study.
Magn Reson Insights., 8 (2015), pp. 1-10
[5]
Sociedad Española de Radiología Médica (SERAM). Posicionamiento de la SERAM respecto a las novedades publicadas sobre seguridad en contrastes con gadolinio [accessed 13 May 2025]. Available from: https://seram.es/posicionamiento-de-la-seram-respecto-a-las-novedades-publicadas-sobre-seguridad-en-contrastes-con-gadolinio/2017.
[6]
F. Lersy, G. Boulouis, O. Clement, H. Desal, R. Anxionnat, J. Berge, et al.
Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology.
J Neuroradiol., 47 (2020), pp. 441-449
[7]
M.F. Bellin, A.J. Van Der Molen.
Extracellular gadolinium-based contrast media: an overview.
Eur J Radiol., 66 (2008), pp. 160-167
[8]
W. Golec, A. Jakimow-Kostrzewa, B. Mruk, S. Jozwiak.
Role of gadolinium-based contrast agents in neurological disorders.
Neurol Neurochir Pol., 54 (2020), pp. 399-409
[9]
M. Port, J.M. Idee, C. Medina, C. Robic, M. Sabatou, C. Corot.
Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
Biometals., 21 (2008), pp. 469-490
[10]
S. Carrasco Munoz, C. Calles Blanco, J. Marcin, C. Fernandez Alvarez, J. Lafuente Martinez.
[Gadolinium-based contrast agents for magnetic resonance imaging].
Radiologia., 56 (2014), pp. 21-28
[11]
O. Bruder, S. Schneider, G. Pilz, A.C. van Rossum, J. Schwitter, D. Nothnagel, et al.
2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large multi-national and multi-ethnical population experience with 37788 patients from the EuroCMR registry.
J Cardiovasc Magn Reson., 17 (2015), pp. 58
[12]
M.S. Nacif, A.E. Arai, J.A. Lima, D.A. Bluemke.
Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
J Cardiovasc Magn Reson., 14 (2012), pp. 18
[13]
T. Grobner.
Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?.
Nephrol Dial Transplant., 21 (2006), pp. 1104-1108
[14]
P. Marckmann, L. Skov, K. Rossen, A. Dupont, M.B. Damholt, J.G. Heaf, et al.
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
J Am Soc Nephrol., 17 (2006), pp. 2359-2362
[15]
Agencia Española de Medicamentos y Productos Sanitarios. Nota informativa de la AEMPS sobre fibrosis sistémica nefrogénica y contrastes de gadolinio: finalización de la revisión en Europa. 2009 [accessed 13 May 2025]. Available from: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2009/NI_2009-12_FSN-gadolinio.htm.
[16]
M.F. Tweedle, P. Wedeking, K. Kumar.
Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Invest Radiol., 30 (1995), pp. 372-380
[17]
Y. Errante, V. Cirimele, C.A. Mallio, V. Di Lazzaro, B.B. Zobel, C.C. Quattrocchi.
Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation.
Invest Radiol., 49 (2014), pp. 685-690
[18]
T. Kanda, K. Ishii, H. Kawaguchi, K. Kitajima, D. Takenaka.
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.
Radiology., 270 (2014), pp. 834-841
[19]
E. Kanal, M.F. Tweedle.
Residual or retained gadolinium: practical implications for radiologists and our patients.
Radiology., 275 (2015), pp. 630-634
[20]
E.M. Gale, P. Caravan.
Gadolinium-free contrast agents for magnetic resonance imaging of the central nervous system.
ACS Chem Neurosci., 9 (2018), pp. 395-397
[21]
Agencia Española de Medicamentos y Productos Sanitarios. Riesgo de formación de depósitos cerebrales asociado a la administración de agentes de contraste con gadolinio. Recomendaciones del Comité europeo para la evaluación de riesgos en farmacovigilancia (PRAC). 2017. [accessed 13 May 2025]. Available from: https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2017/ni-muh_fv_02-gadolinio/.
[22]
European Medicines Agency. Gadolinium-containing contrast agents - referral. 2017 [accessed 13 May 2025]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents.
[23]
A. Chazot, J.A. Barrat, M. Gaha, R. Jomaah, J. Ognard, D. Ben Salem.
Brain MRIs make up the bulk of the gadolinium footprint in medical imaging.
J Neuroradiol., 47 (2020), pp. 259-265
[24]
P. Soyer, A. Dohan, D. Patkar, A. Gottschalk.
Observational study on the safety profile of gadoterate meglumine in 35,499 patients: the SECURE study.
J Magn Reson Imaging., 45 (2017), pp. 988-997
[25]
European Society of Urogenital Radiology (ESUR). Guías ESUR sobre agentes de contraste 10.0. 2022 [accessed 13 May 2025]. Available from: https://www.esur.org/wp-content/uploads/2023/04/ESUR_Guidelines_10.0_Final_Version_SPANISH_2022.pdf.
[26]
Agencia española de Medicamentos y Productos Sanitarios. Riesgo de formación de depósitos cerebrales asociado a la administración de agentes de contraste con gadolinio: actualización de la información. 2017 [accessed 13 May 2025]. Available from: http://aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2017/ni-muh_fv_07-2017-gadolinio/.
[27]
Ficha técnica Gadovist 1 mmol/ml solución inyectable en vial [accessed 13 May 2025]. Available from: https://cima.aemps.es/cima/dochtml/ft/63535/FichaTecnica_63535.html.
[28]
Ficha técnica Dotarem 0,5mmol/ml [accessed 13 May 2025]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/67489/67489_ft.pdf.
[29]
Ficha Técnica ProHance 279,3mg/ml solución inyectable [accessed 13 May 2025]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/60377/60377_ft.pdf.
[30]
F. Iacobellis, M. Di Serafino, C. Russo, R. Ronza, M. Caruso, G. Dell’Aversano Orabona, et al.
Safe and informed use of gadolinium-based contrast agent in body magnetic resonance imaging: where we were and where we are.
J Clin Med., 13 (2024), pp. 2193
[31]
J.G. Ray, M.J. Vermeulen, A. Bharatha, W.J. Montanera, A.L. Park.
Association between MRI exposure during pregnancy and fetal and childhood outcomes.
JAMA., 316 (2016), pp. 952-961
[32]
A. Heshmatzadeh Behzadi, J. McDonald.
Gadolinium-based contrast agents for imaging of the central nervous system: a multicenter European prospective study.
Medicine (Baltimore)., 101 (2022),
[33]
F.L. Giesel, A. Mehndiratta, M. Essig.
High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review.
Eur Radiol., 20 (2010), pp. 2461-2474
[34]
L. Frontera Valero, A. Hodgert, D. Castro Vidal, M. Bellido Padilla, J. Pardo Maiza, M.M. Centelles-Oria, et al.
Retos para entender la relevancia del depósito de gadolinio tras su administración en resonancia magnética.
An RANM., 141 (2024), pp. 266-273
[35]
A. Rovira, D. Ben Salem, A.F. Geraldo, S. Cappelle, A. Del Poggio, S. Cocozza, et al.
Go Green in Neuroradiology: towards reducing the environmental impact of its practice.
Neuroradiology., 66 (2024), pp. 463-476
[36]
A. Sengar, A. Vijayanandan.
Comprehensive review on iodinated X-ray contrast media: Complete fate, occurrence, and formation of disinfection byproducts.
[37]
G. Trapasso, S. Chiesa, R. Freitas, E. Pereira.
What do we know about the ecotoxicological implications of the rare earth element gadolinium in aquatic ecosystems?.
[38]
Z. Zhang, W. Jiang, T. Gu, N. Guo, R. Sun, Y. Zeng, et al.
Anthropogenic gadolinium contaminations in the marine environment and its ecological implications.
[39]
R. Brunjes, T. Hofmann.
Anthropogenic gadolinium in freshwater and drinking water systems.
[40]
P. Ebrahimi, M. Barbieri.
Gadolinium as an emerging microcontaminant in water resources: threats and opportunities.
Geosciences., 9 (2019), pp. 93
[41]
C. Mossotto, S. Anselmi, S. Trevisan, F. Provenza, A. Maganz, A. Gabetti, et al.
Assessing the toxicity of gadolinium in freshwater and marine ecosystems: effects across trophic levels.
Environ Toxicol Pharmacol., 115 (2025),
[42]
J. Ognard, J.A. Barrat, A. Chazot, Z. Alavi, D. Ben Salem.
Gadolinium footprint: cradle to cradle?.
J Neuroradiol., 47 (2020), pp. 247-249
[43]
J. Hao, C. Pitrou, P. Bourrinet.
A comprehensive overview of the efficacy and safety of gadopiclenol: a new contrast agent for MRI of the CNS and body.
Invest Radiol., 59 (2024), pp. 124-130
[44]
J. Haubold, R. Hosch, G. Jost, F. Kreis, M. Forsting, H. Pietsch, et al.
AI as a new frontier in contrast media research: bridging the gap between contrast media reduction, the contrast-free question and new application discoveries.
Invest Radiol., 59 (2024), pp. 206-213
[45]
R. Haase, T. Pinetz, E. Kobler, Z. Bendella, D. Paech, R. Clauberg, et al.
Metastasis detection using true and artificial T1-weighted postcontrast images in brain MRI.
Invest Radiol., 60 (2025), pp. 340-348
[46]
S. Ammari, A. Bône, C. Balleyguier, E. Moulton, É. Chouzenoux, A. Volk, et al.
Can deep learning replace gadolinium in neuro-oncology?: A reader study.
Invest Radiol., 57 (2022), pp. 99-107
[47]
M.C. DeLano, M.V. Spampinato, E.Y. Chang, R.G. Barr, R.J. Lichtenstein, C. Colosimo, et al.
Dose-lowering in contrast-enhanced MRI of the central nervous system: a retrospective, parallel-group comparison using gadobenate dimeglumine.
J Magn Reson Imaging., 54 (2021), pp. 1660-1675
[48]
J. Endrikat, M. Gutberlet, J. Barkhausen, L. Schöckel, A. Bhatti, C. Harz, et al.
Clinical efficacy of gadobutrol: review of over 25 years of use exceeding 100 million administrations.
Invest Radiol., 59 (2024), pp. 345-358
[49]
D. Haba, A. Pasco Papon, J.Y. Tanguy, P. Burtin, C. Aube, C. Caron-Poitreau.
Use of half-dose gadolinium-enhanced MRI and magnetization transfer saturation in brain tumors.
Eur Radiol., 11 (2001), pp. 117-122
[50]
J.Q. He, M. Iv, G. Li, M. Zhang, M. Hayden Gephart.
Noncontrast T2-weighted magnetic resonance imaging sequences for long-term monitoring of asymptomatic convexity meningiomas.
World Neurosurg., 135 (2020), pp. e100-e105
[51]
B.P. Liu, M. Rosenberg, P. Saverio, Y.C. Weon, S. Peters, F.D. Ardellier, et al.
Clinical efficacy of reduced-dose gadobutrol versus standard-dose gadoterate for contrast-enhanced MRI of the CNS: an International Multicenter Prospective Crossover Trial (LEADER-75).
AJR Am J Roentgenol., 217 (2021), pp. 1195-1205
[52]
L.A. Loevner, B. Kolumban, G. Hutóczki, K. Dziadziuszko, D. Bereczki, A. Bago, et al.
Efficacy and safety of gadopiclenol for contrast-enhanced MRI of the central nervous system: the PICTURE Randomized Clinical Trial.
Invest Radiol., 58 (2023), pp. 307-313
[53]
E. Maloney, A.L. Stanescu, F.A. Perez, R.S. Iyer, R.K. Otto, S. Leary, et al.
Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?.
Pediatr Radiol., 48 (2018), pp. 1472-1484
[54]
K.R. Maravilla, D. San-Juan, S.J. Kim, G. Elizondo-Riojas, J.R. Fink, W. Escobar, et al.
Comparison of gadoterate meglumine and gadobutrol in the MRI diagnosis of primary brain tumors: a double-blind randomized controlled intraindividual crossover study (the REMIND study).
AJNR Am J Neuroradiol., 38 (2017), pp. 1681-1688
[55]
K.R. Maravilla, M.P. Smith, J. Vymazal, M. Goyal, M. Herman, J.J. Baima, et al.
Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
AJNR Am J Neuroradiol., 36 (2015), pp. 14-23
[56]
S. Sathraju, K. Johnson, K.V. Cicalese, C.F. Opalak, W.C. Broaddus.
Reducing gadolinium exposure in patients undergoing monitoring for meningiomas.
[57]
Z. Seidl, J. Vymazal, M. Mechl, M. Goyal, M. Herman, C. Colosimo, et al.
Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).
AJNR Am J Neuroradiol., 33 (2012), pp. 1050-1058
[58]
M. Vaneckova, M. Herman, M.P. Smith, M. Mechl, K.R. Maravilla, J. Weichet, et al.
The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study).
AJNR Am J Neuroradiol., 36 (2015), pp. 1589-1598
[59]
S.M. Alonso, F. Lersy, F.D. Ardellier, H. Cebula, F. Proust, A. Onofrei, et al.
Is non-contrast MRI sufficient to detect meningioma residue after surgery?.
J Neuroradiol., 51 (2024), pp. 176-181
[60]
S. Bayraktaroğlu, E. Pabuçcu, N. Ceylan, S. Duman, R. Savaş, H. Alper.
Evaluation of the necessity of contrast in the follow-up MRI of schwannomas.
Diagn Interv Radiol., 17 (2011), pp. 209-215
[61]
J. Boto, R. Guatta, A. Fitsiori, J. Hofmeister, T.R. Meling, M.I. Vargas.
Is contrast medium really needed for follow-up MRI of untreated intracranial meningiomas?.
AJNR Am J Neuroradiol., 42 (2021), pp. 1421-1428
[62]
D.H. Coelho, Y. Tang, B. Suddarth, M. Mamdani.
MRI surveillance of vestibular schwannomas without contrast enhancement: clinical and economic evaluation.
Laryngoscope., 128 (2018), pp. 202-209
[63]
T. Dowers, A. Helmi, A.N. Mbanwi, P. Alcaide-Leon.
Comparative evaluation of lower gadolinium doses for MR imaging of meningiomas: how low can we go?.
AJNR Am J Neuroradiol., 45 (2024), pp. 1762-1768
[64]
I.F. Dunn, W.L. Bi, S. Mukundan, B.N. Delman, J. Parish, T. Atkins, et al.
Congress of neurological surgeons systematic review and evidence-based guidelines on the role of imaging in the diagnosis and management of patients with vestibular schwannomas.
Neurosurgery., 82 (2018), pp. E32-e4
[65]
M. Forgues, R. Mehta, D. Anderson, C. Morel, L. Miller, A. Sevy, et al.
Non-contrast magnetic resonance imaging for monitoring patients with acoustic neuroma.
J Laryngol Otol., 132 (2018), pp. 780-785
[66]
R. Goldbrunner, P. Stavrinou, M.D. Jenkinson, F. Sahm, C. Mawrin, D.C. Weber, et al.
EANO guideline on the diagnosis and management of meningiomas.
Neuro Oncol., 23 (2021), pp. 1821-1834
[67]
A. Karol, F. Veillon, T. Huynh, F. Severac, A. Charpiot, A. Venkatasamy.
Is an intravenous injection of gadolinium really necessary for intralabyrinthine schwannomas MR examination?.
Otol Neurotol., 39 (2018), pp. e579-e584
[68]
R. Ludovichetti, B. Delattre, J. Boto, D. LaGrange, T. Meling, M.I. Vargas.
Characterization of meningiomas with synthetic imaging.
Brain Behav., 12 (2022), pp. e2769
[69]
D. Raban, S.H. Patel, J.M. Honce, D. Rubinstein, P.E. DeWitt, V.M. Timpone.
Intracranial meningioma surveillance using volumetrics from T2-weighted MRI.
J Neuroimaging., 32 (2022), pp. 134-140
[70]
F.K. Rahatli, F.Y. Donmez, C. Kesim, K.M. Haberal, H. Turnaoglu, A.M. Agildere.
Can unenhanced brain magnetic resonance imaging be used in routine follow up of meningiomas to avoid gadolinium deposition in brain?.
Clin Imaging., 53 (2019), pp. 155-161
[71]
Y. Yao, Y. Xu, S. Liu, F. Xue, B. Wang, S. Qin, et al.
Predicting the grade of meningiomas by clinical-radiological features: a comparison of precontrast and postcontrast MRI.
[72]
D.H. Kim, S. Lee, S.H. Hwang.
Non-contrast magnetic resonance imaging for diagnosis and monitoring of vestibular schwannomas: a systematic review and meta-analysis.
Otol Neurotol., 40 (2019), pp. 1126-1133
[73]
P.C. Davis, K.A. Gokhale, G.J. Joseph, S.B. Peterman, D.A. Adams, G.T. Tindall, et al.
Pituitary adenoma: correlation of half-dose gadolinium-enhanced MR imaging with surgical findings in 26 patients.
Radiology., 180 (1991), pp. 779-784
[74]
A. Villemaire, G. Adam, H. Fayolle, M. Roques, J. Darcourt, P. Caron, et al.
Is systematic Gadolinium injection relevant during MRI follow-up for non-functioning pituitary macroadenomas?.
J Neuroradiol., 50 (2023), pp. 3-8
[75]
A.A. Alali, P.B. Hanagandi, P.J. Maralani.
Do we need gadolinium-based contrast agents for routine MRI surveillance of unoperated pituitary macroadenoma?.
AJNR Am J Neuroradiol., 43 (2022), pp. 1024-1028
[76]
K.S. Subedi, T. Takahashi, T. Yamano, J. Saitoh, K. Nishimura, Y. Suzuki, et al.
Usefulness of double dose contrast-enhanced magnetic resonance imaging for clear delineation of gross tumor volume in stereotactic radiotherapy treatment planning of metastatic brain tumors: a dose comparison study.
J Radiat Res., 54 (2013), pp. 135-139
[77]
A. Rovira, C. Auger, E. Huerga, J.F. Corral, R. Mitjana, J. Sastre-Garriga, et al.
Cumulative dose of macrocyclic gadolinium-based contrast agent improves detection of enhancing lesions in patients with multiple sclerosis.
AJNR Am J Neuroradiol., 38 (2017), pp. 1486-1493
[78]
À. Rovira, F.M. Doniselli, C. Auger, L. Haider, J. Hodel, M. Severino, et al.
Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.
Eur Radiol., 34 (2024), pp. 1726-1735
[79]
S. Christensen, S. Amukotuwa, M.G. Lansberg, S. Kemp, J.J. Heit, M. Mlynash, et al.
Comparison of Tmax values between full- and half-dose gadolinium perfusion studies.
J Cereb Blood Flow Metab., 41 (2021), pp. 336-341
asdasdasd
Article options
Tools